Wedbush Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB)
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a $40.00 target price on the biotechnology company’s stock. Wedbush’s price objective indicates a potential upside of 107.36% from the company’s previous close. Other research analysts […]
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a $40.00 target price on the biotechnology company’s stock. Wedbush’s price objective indicates a potential upside of 107.36% from the company’s previous close. Other research analysts […]
